← Leaderboards
Jay A Barth
Ptc Therapeutics, Inc.
$3,397,697
Attributed
$3,397,697
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2010–16$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
FDA$2,899,482 · 4
NIH$498,215 · 1
By mechanism
R01$2,899,482 · 4
RC1$498,215 · 1
Top collaborators
No co-investigators on record.
Most similar at Ptc Therapeutics, Inc.
Same institution · by research overlap
- Langdon Leforrest Miller$1,455,058
- Robert J Spiegel$399,984
Others in their field
Top investigators on “Adult”
- Lawrence Corey · Fred Hutchinson Cancer Center$594,628,824
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$397,114,680
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$388,038,550
- Judith S. Currier · University Of California Los Angeles$251,592,913
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$196,603,707
- Carol Nesel · Westat$188,148,170
Research focus
AdultAffectAnimal ModelAnimalsAreaBaseBioavailableBiological ProductsBlood Coagulation FactorCatheter Related InfectionClinical Practice GuidelineClinical TrialsCommunitiesComplicationControlled StudyCostCouplingCystic FibrosisDefectDesignDisease TransmissionDocumentationDoseAchievement
Grant awards (9)
SD-101 Cream to Treat Epidermolysis Bullosa Phase 3 IND107480 12/20/12$500,000
R01 · FY2016 · FD · contact PI
Phase 3 Study of PTC124 in Cystic Fibrosis (IND 48,648)$399,984
R01 · FY2012 · FD · contact PI
Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystrophy (IND 68,431)$398,393
R01 · FY2012 · FD · contact PI
Phase 3 Study of PTC124 in Cystic Fibrosis (IND 48,648)$399,984
R01 · FY2011 · FD · contact PI
Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystrophy (IND 68,431)$398,393
R01 · FY2011 · FD · contact PI
Phase 2a Study of Ataluren in Hemophilia A and B (IND 104,321)$498,215
RC1 · FY2010 · HL · contact PI
Phase 3 Study of PTC124 in Cystic Fibrosis (IND 48,648)$399,984
R01 · FY2010 · FD · contact PI
Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystrophy (IND 68,431)$398,393
R01 · FY2010 · FD · contact PI
Phase 2 Study of PTC299 in Glioblastoma Multiforme (IND 71,033)$4,351
R01 · FY2010 · FD · contact PI